Medivir AB (MVRBF): Simeprevir Receives Positive CHMP Opinion For The Treatment Of Adults With Chronic Hepatitis C In The European Union
3/21/2014 9:44:39 AM
Medivir AB (OMX: MVIR) (STO:MVIR-B) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by